Email Us
Call Us
AUSTIN, Texas – March 14, 2023 – Research generated at Altogen Labs has been indexed within many citation databases including Sigma-Aldrich (Merck KGaA) where the company’s glioblastoma study appears among the validating references associated with pyruvate dehydrogenase kinase (PDK) detection reagents. The underlying study, published in Cancer Biology & Therapy, evaluated eight structurally modified dichloroacetate analogs and identified two cationic compounds that inhibited tumor growth in the U87 human glioblastoma xenograft model. The in vitro screening, in vivo efficacy work, and downstream immunoblotting of tumor lysates were conducted at the Altogen Labs facility in Austin, Texas.
The study illustrates the integrated capability Altogen Labs brings to sponsor programs — cell line viability screening across multiple tumor types, selection of lead candidates, in vivo efficacy testing in validated xenograft models under IACUC-regulated and GLP-compliant conditions, and mechanistic protein-level analysis of harvested tumor tissue using automated capillary Western systems. Altogen Labs offers this sequence across its full validated collection, spanning brain, breast, lung, colorectal, gastric, pancreatic, prostate, ovarian, kidney, liver, melanoma, sarcoma, leukemia, and lymphoma models, in CDX, PDX, syngeneic, organoid, and NAM formats.
About Altogen Labs Altogen Labs is a professional, experienced, and highly reputable GLP-compliant contract research organization providing preclinical research and biology CRO services to pharmaceutical, biotechnology, and academic institutions worldwide, with a large portfolio of validated xenograft models and extensive experience in efficacy xenograft and safety toxicology studies.
Contact Information: Altogen Labs | 11200 Menchaca Rd, Bldg 2, Suite 203 | Austin, TX 78748 USA Tel: 512-433-6177 | Email: info@altogenlabs.com | Web: altogenlabs.com